Ignite Creation Date:
2025-12-24 @ 11:39 PM
Ignite Modification Date:
2026-01-03 @ 8:47 PM
Study NCT ID:
NCT06001151
Status:
RECRUITING
Last Update Posted:
2023-08-21
First Post:
2023-08-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative
Sponsor:
Qian Chu
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
S019
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | OTHER | View |